Strict-anaerobe workflows (Hungate/roll-tube, oxygen-free plating) isolate B. dorei from fecal or biobank materials. We purify colonies, stabilize phenotypes, and pre-screen B. dorei for growth kinetics, bile resistance, carbohydrate use, and redox tolerance—building an initial decision dossier while preserving voucher stocks for downstream assays at Creative Biolabs.
We confirm B. dorei by 16S rRNA plus whole-genome sequencing—reporting ANI, phylogenomics, and in-silico typing. Our genome summary flags polysaccharide utilization loci (PULs), stress-tolerance genes, BSH candidates, and coprostanol-pathway markers (e.g., ismA-like signatures), giving you a feature-rich, publication-ready identity package before functional profiling of B. dorei begins.
We design and validate B. dorei-specific qPCR/ddPCR assays with cross-reactivity testing against close relatives (e.g., B. vulgatus, B. uniformis). Assays are optimized for absolute quantification of B. dorei in fecal, bioreactor, or formulated matrices, with SOP transfer and controls to standardize monitoring across sites.
From anaerobic shake-flasks to instrumented benchtop bioreactors, we tailor B. dorei cultivation: media and carbon-source optimization, pH/redox control, fed-batch strategies, and on-line gas monitoring. Short-chain fatty acids are tracked by GC/HPLC, while viability and stability guide harvest windows, cryoprotectant selection, and bankable lots of B. dorei for repeatable studies.
We parse B. dorei glycan use with Biolog AN panels and custom substrates (inulin, resistant starches, mucin-derived glycans, and selected HMOs). Readouts include SCFA fingerprints, residual sugar analytics, and pathway notes linked to relevant PULs—informing prebiotic pairing and functional hypothesis building specific to B. dorei.
Assay panels tailored to B. dorei explore bile-salt tolerance, mucus interaction, PUL activity readouts, epithelial barrier markers, and metabolite–phenotype correlations (e.g., BSH/bile-acid profiles vs. TEER changes). Output is a coherent mechanism narrative for B. dorei, supported by orthogonal datasets and well-annotated raw files.
With Caco-2/HT29-MTX monolayers, primary organoids, or mucus-rich co-cultures, we quantify B. dorei adhesion, barrier integrity (TEER, claudins/occludin), mucin dynamics, and cytokine baselines. Optional bile-acid supplementation and cholesterol spiking help dissect FXR/TGR5 and coprostanol-linked responses to B. dorei under realistic epithelial conditions.
PBMC and dendritic-cell co-cultures, plus TLR/NF-κB reporter lines, map B. dorei-induced cytokines (IL-6, IL-8, IL-10, TNF-α) to live cells, lysates, or postbiotics. Time-course designs capture early type-I interferon patterns and dose–response curves, generating decision-ready immune profiles for B. dorei.
